Category: Ocrevus

#AAN2018 — Ocrevus Lowers Immune Response to Vaccines in Relapsing MS, Phase 3 Trial Shows

Treatment with Ocrevus (ocrelizumab) is linked to a reduced immune response to vaccinations in patients with relapsing multiple sclerosis (MS), according to a Phase…

Stuart Schlossman

The History of Ocrevus’ – The Journey from Defiant Idea to Game-Changing Treatment

Information found below was acquired from MS NewsToday Link Twenty years ago, the idea that B-cell depletion could treat multiple…

Stuart Schlossman

Ocrelizumab More Cost-Effective Than Interferon

J Med Econ; 2017 Oct; Yang, Duchesneau, et al November 21, 2017 Ocrelizumab is more cost-effective than subcutaneous (SC) interferon…

Stuart Schlossman

New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis

·       Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity…

Stuart Schlossman

Ocrelizumab Offers Greater Value Than Interferon

J Med Econ; 2017 Oct; Frasco, Shih, Incerti, et al October 17, 2017 Ocrelizumab provides greater value to relapsing forms…

Stuart Schlossman

UCSF Neurologist Played Key Role in MS Research Turning to B-Cells, Essential Step to Ocrevus

                                       …

Stuart Schlossman

Ocrevus Phase 3 Trial Will Explore How Treatment Works by Viewing Changes in Spinal Fluid

                                       …

Stuart Schlossman

OhioHealth hospital was the first to use the FDA Approved Drug, Ocrevus

                                       …

Stuart Schlossman

Categories

Latest Blog Posts